Review

Venous gangrene and cancer: A cool look at a burning issue

Khalid A Osman¹ , Mohamed H Ahmed² , Samir A Abdulla¹ , Tim E Bucknall¹ and Colin A Rogers¹

¹Department of Surgery, Queen's Hospital, Burton Hospitals NHS Trust, Staffordshire, UK

²Department of Chemical Pathology, Southampton General Hospital, Southampton, UK

author email corresponding author email

International Seminars in Surgical Oncology 2007, 4:7doi:10.1186/1477-7800-4-7

Published:	27 March 2007

Abstract

Venous gangrene (VG) is defined as a clinical triad of skin necrosis and discolouration, documented evidence of venous thromboembolism (VTE) and presence of palpable or doppler- identifiable arterial pulsation. Venous gangrene is rare condition which is associated with poor prognosis in cancer patients. The pathogenesis of VG is multifactorial and could paradoxically be due to warfarin treatment. Heparin Induced Thrombocytopenia (HIT) associated venous gangrene develops when heparin therapy is discontinued and warfarin therapy initiated or continued.

It has been reported that the presence of anticardiolipin antibodies appears to double the risk of thrombo-embolic events in cancer patients in comparison with those who are anticardiolipin antibody negative. The presence of anticardiolipin antibodies is therefore a warning sign for venous gangrene in cancer patients. Hypercoagulable state associated with malignancy, cancer treatment, prolonged immobilisation, surgical operations and metabolic syndrome are all associated with increased risk of VTE and VG.

The current evidence suggests that cancer patients are at increased risk from recurrent venous thrombosis and venous gangrene, and LMWH provides potential promise as a safe and effective measure in the management of such patients.